Early-Stage Clinical Development
Agilent supports your clinical development program with high-quality oligonucleotides produced under current Good Manufacturing Practices (cGMP), whether you need grams for toxicology studies and early-stage clinical trials or tens of kilograms for late-stage trials and commercialization.
Advance your oligo candidates to market-approved therapies with a partner that assists you throughout your clinical program. Agilent is the listed manufacturer on over 100 investigational new drug applications (INDs), and our cGMP facilities currently manufacture six commercially approved oligo therapeutics.
Advance your oligo candidates to market-approved therapies with a partner that assists you throughout your clinical program. Agilent is the listed manufacturer on over 100 investigational new drug applications (INDs), and our cGMP facilities currently manufacture six commercially approved oligo therapeutics.